Immunomic Therapeutics, Inc. CEO, William Hearl, Ph.D. to Speak at 2015 BIO International Convention

HERSHEY, Pa. and ROCKVILLE, Md., June 3, 2015 (GLOBE NEWSWIRE) -- Immunomic Therapeutics, Inc. ("ITI"), a privately-held biotechnology company developing vaccines based on its proprietary LAMP technology, today announces that the company's CEO, William Hearl, Ph.D., will be one of the featured speakers at this year's Biotechnology Industry Organization (BIO) International Convention on June 15-18 at the Pennsylvania Convention Center in Philadelphia.

Dr. Hearl will be discussing the company's LAMP-vax platform technology, as well as current plans. He will be speaking on Wednesday, June 17th at 9:45 AM (EDT) as part of the Vaccines track in Theater 3, dubbed "Doctor Nucleus." In addition, the company will have an exhibition booth at the Pennsylvania Pavilion, #4227. For planning purposes, please visit:

"We are gratified for the opportunity to address our industry peers at BIO to discuss Immunomic's unique approach to solving the allergy problem," said Dr. Hearl. "The BIO convention has long been an opportunity to share ideas, create new collaborations and take note of what's happening in our industry."

About Immunomic Therapeutics, Inc.

Immunomic Therapeutics, Inc. (ITI) is a Hershey, PA-based, privately held, clinical stage biotechnology company developing vaccines based on the LAMP technology platform, which was exclusively licensed from Johns Hopkins University. The LAMP-vax vaccine platform aims to increase the immune response to nucleic acid vaccines and simplify vaccine design and delivery for safer, more cost-effective therapies. ITI's LAMP constructs have been validated in human clinical trials for cancer and have been studied in areas including allergy and infectious disease, while internally ITI is focused on developing allergy therapies. Currently, the company is pursuing three main allergy programs:

  • ASP 4070 (Formerly known as JRC-LAMP-vax) - Japanese Red Cedar Vaccine - An innovative potential solution for the over 35 million sufferers of Japanese red cedar pollinosis - Phase I, currently partnered with Astellas Pharma;
    • An analogous vaccine formulation will be developed as a vaccine to treat Mountain Cedar in the US.
  • ARA-LAMP-vax Peanut Allergy Vaccine - A therapeutic vaccine in development, with a goal of mitigating peanut allergy - Beginning Phase I in late 2015/early 2016;
  • Multi Allergen Vaccines (Product Concepts) - Allergy vaccine formulation concepts that would aim to address the major categories of allergies of concern Worldwide - Under study & development.

For more information about ITI and LAMP Technology, please visit

CONTACT: Jules Abraham JQA Partners, Inc. 917-885-7378 jabraham@jqapartners.comSource:Immunomic Therapeutics, Inc.